UnitedHealth raised its full-year 2026 adjusted earnings outlook to at least $20.50 a share after a sharp third-quarter profit recovery. Revenue was $112.7 billion and earnings from operations reached $6.6 billion, up 52% from a year earlier. The improvement came from lower medical and operating cost ratios, but the quarter also showed weaker membership and revenue in parts of the business.
The medical-cost turn
UnitedHealth's medical care ratio improved to 88.4% from 89.9% a year earlier. The ratio shows how much premium revenue is spent on medical care, so a 1.5 percentage-point decline means more premium dollars remained to cover administration and profit. Management attributed the change to pricing, benefit adjustments, medical-cost management and a $610 million favorable reserve development.
The operating cost ratio fell to 12.8% from 13.5%. Together, the two ratio improvements explain why adjusted earnings rose to $4.69 a share from $2.92 even though consolidated revenue slipped 0.4%. Cash flow from operations was $5.1 billion, equal to 1.2 times net income, while debt represented 41.7% of total capital at quarter-end.
Recovery is uneven
UnitedHealthcare generated $86.3 billion of revenue, down from $87.1 billion, while operating earnings rose to $2.8 billion from $1.8 billion. The insurance unit served 48.3 million people, about 1.8 million fewer than a year earlier. That combination suggests the profit recovery relied more on pricing and cost discipline than on membership growth.
Optum produced $66.9 billion of revenue and $3.7 billion of operating earnings. Within it, Optum Health revenue fell 10% to $22.9 billion as the company served fewer patients in markets where its value-based care operations lacked scale. Operating earnings at Optum Health nevertheless rose to $735 million from $41 million, another sign that management is shrinking or repairing low-return activity.
What the guidance says
The new adjusted EPS floor is above the previous range of $19.50 to $20.00. It incorporates the third-quarter improvement, but an annualized reserve benefit or cost action should not automatically be treated as recurring growth. The company also returned $11.2 billion through repurchases and dividends in the first nine months, a substantial use of cash during an operational reset.
The next test is whether the medical care ratio remains lower without further membership erosion. Investors should also watch Optum Health patient trends and cash conversion. If those measures stabilize, the higher guidance will look like a durable operating recovery. If not, the quarter may prove to be a strong cost reset masking slower underlying growth.